# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Atea Pharmaceuticals announces 97% SVR12 in Phase 2 HCV study of bemnifosbuvir. Data shows high efficacy, safety, and low resis...
97% SVR12 Rate Observed with 8 Weeks of Treatment in Lead-In Cohort of HCV-Infected Patients in Ongoing Phase 2 Clinical Stud...
Atea Pharmaceuticals (NASDAQ:AVIR) reported quarterly losses of $(0.75) per share which missed the analyst consensus estimate o...
Atea Pharmaceuticals (NASDAQ:AVIR) reported quarterly losses of $(0.47) per share which beat the analyst consensus estimate of ...
Companies Reporting Before The Bell • ICL Group (NYSE:ICL) is likely to report quarterly earnings at $0.08 per share on revenu...